Here’s why Eli Lilly will sell a generic insulin

Marielle Segarra Mar 4, 2019
Share Now on:
HTML EMBED:
COPY

Here’s why Eli Lilly will sell a generic insulin

Marielle Segarra Mar 4, 2019
Share Now on:
HTML EMBED:
COPY

Indianapolis-based pharmaceutical company Eli Lilly announced Monday that it will sell a generic version of Humalog, its branded insulin product. The generic will cost $137 per vial, or half as much as Humalog. Lilly’s move is seen as a partial concession to lawmakers who have grilled pharma companies about the high cost of life-saving prescription drugs. But the company will keep Humalog at its current price. Why this two-tiered drug strategy?

Click the audio player above to hear the full story.

If you’re a member of your local public radio station, we thank you — because your support helps those stations keep programs like Marketplace on the air.  But for Marketplace to continue to grow, we need additional investment from those who care most about what we do: superfans like you.

Your donation — as little as $5 — helps us create more content that matters to you and your community, and to reach more people where they are – whether that’s radio, podcasts or online.

When you contribute directly to Marketplace, you become a partner in that mission: someone who understands that when we all get smarter, everybody wins.

We’re here for you.

As COVID-19 reshapes our economy, our newsletter will help you unpack the news from the day.